Fate Therapeutics (NASDAQ:FATE)‘s stock had its “overweight” rating restated by Piper Jaffray Companies in a research report issued to clients and investors on Tuesday, September 18th, The Fly reports. They currently have a $25.00 price target on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price target would indicate a potential upside of 85.05% from the stock’s previous close.

A number of other analysts also recently commented on FATE. BidaskClub upgraded shares of Fate Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 22nd. Zacks Investment Research upgraded shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 17th. Citigroup assumed coverage on shares of Fate Therapeutics in a report on Wednesday, August 1st. They set a “buy” rating and a $20.00 price target on the stock. HC Wainwright restated a “hold” rating and set a $12.00 price target on shares of Fate Therapeutics in a report on Tuesday, August 7th. Finally, Wedbush restated an “outperform” rating and set a $19.00 price target on shares of Fate Therapeutics in a report on Tuesday, August 7th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $17.29.

Shares of FATE stock traded up $0.21 during midday trading on Tuesday, reaching $13.51. 656,579 shares of the company were exchanged, compared to its average volume of 648,599. Fate Therapeutics has a 12 month low of $3.50 and a 12 month high of $16.94. The company has a market capitalization of $870.20 million, a price-to-earnings ratio of -13.25 and a beta of 1.72. The company has a current ratio of 4.92, a quick ratio of 4.92 and a debt-to-equity ratio of 0.25.

Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). Fate Therapeutics had a negative return on equity of 95.07% and a negative net margin of 1,387.53%. The company had revenue of $1.00 million for the quarter, compared to the consensus estimate of $1.02 million. The business’s revenue for the quarter was up .0% on a year-over-year basis. On average, equities research analysts predict that Fate Therapeutics will post -1.16 earnings per share for the current year.

In related news, Director Redmile Group, Llc acquired 3,703,704 shares of the stock in a transaction that occurred on Tuesday, September 25th. The shares were purchased at an average cost of $13.50 per share, with a total value of $50,000,004.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.89% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Northern Trust Corp grew its position in Fate Therapeutics by 14.4% in the second quarter. Northern Trust Corp now owns 568,272 shares of the biopharmaceutical company’s stock worth $6,444,000 after acquiring an additional 71,353 shares in the last quarter. Moody Aldrich Partners LLC bought a new stake in shares of Fate Therapeutics during the 2nd quarter worth $946,000. Bank of New York Mellon Corp boosted its holdings in shares of Fate Therapeutics by 5.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 290,529 shares of the biopharmaceutical company’s stock worth $3,294,000 after buying an additional 13,839 shares during the period. Jane Street Group LLC bought a new stake in shares of Fate Therapeutics during the 2nd quarter worth $116,000. Finally, California Public Employees Retirement System bought a new stake in shares of Fate Therapeutics during the 2nd quarter worth $193,000. 80.61% of the stock is owned by institutional investors.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors.

Further Reading: Dow Jones Industrial Average (DJIA)

The Fly

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.